dc.contributor.author | Popat, S | |
dc.contributor.author | Hsia, T-C | |
dc.contributor.author | Hung, J-Y | |
dc.contributor.author | Jung, HA | |
dc.contributor.author | Shih, J-Y | |
dc.contributor.author | Park, CK | |
dc.contributor.author | Lee, SH | |
dc.contributor.author | Okamoto, T | |
dc.contributor.author | Ahn, HK | |
dc.contributor.author | Lee, YC | |
dc.contributor.author | Sato, Y | |
dc.contributor.author | Lee, SS | |
dc.contributor.author | Mascaux, C | |
dc.contributor.author | Daoud, H | |
dc.contributor.author | Märten, A | |
dc.contributor.author | Miura, S | |
dc.date.accessioned | 2022-05-27T14:45:23Z | |
dc.date.available | 2022-05-27T14:45:23Z | |
dc.identifier.citation | The oncologist, 2022, 27 (4), pp. 255 - 265 | en |
dc.identifier.issn | 1083-7159 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5159 | |
dc.identifier.eissn | 1549-490X | en_US |
dc.identifier.eissn | 1549-490X | |
dc.identifier.doi | 10.1093/oncolo/oyac022 | en_US |
dc.identifier.doi | 10.1093/oncolo/oyac022 | |
dc.description.abstract | <h4>Background</h4>Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are standard of care for patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) with common mutations (Del19 or L858R); however, 7%-23% of NSCLC tumors harbor uncommon EGFR mutations. These mutations are highly heterogeneous, and developments in detection techniques are helping to identify mutations with little or no clinical data.<h4>Patients and methods</h4>In this retrospective, global, multi-center study (NCT04179890), existing health records were identified for consecutive EGFR TKI-naïve patients with uncommon EGFR mutations (T790M, ex20ins, major uncommon [G719X, L861Q, or S768I], or "other" mutations; compound mutations) treated with erlotinib, gefitinib, afatinib, or osimertinib in first or second line. Endpoints included time-to-treatment failure (TTF), objective response rate (ORR), and overall survival (OS).<h4>Results</h4>Overall, 246 patients (median age: 69.5 years; Asian: 84%) were included from 9 countries. Most patients (92%) received an EGFR TKI as first-line therapy; 54%, 43% and 3% received afatinib, first-generation TKIs, and osimertinib, respectively. Median TTF and OS with EGFR TKIs were 9.9 and 24.4 months; ORR was 43%. In patients treated with first-line chemotherapy (n = 20), median TTF and ORR were 6.6 months and 41%. Outcomes were most favorable in patients with major uncommon or compound mutations. Overall, TTF was 11.3 months with afatinib and 8.8 months with first-generation EGFR TKIs across mutation categories. In most mutation categories, median OS was >2 years.<h4>Conclusion</h4>In a real-world setting, EGFR TKIs were the preferred treatment option in patients with uncommon EGFR mutations; strongest outcomes were seen in patients with major uncommon and compound mutations. | en_US |
dc.format | Print | en_US |
dc.format.extent | 255 - 265 | en_US |
dc.language | eng | en_US |
dc.language.iso | eng | en |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en |
dc.subject | Humans | en_US |
dc.subject | Carcinoma, Non-Small-Cell Lung | en_US |
dc.subject | Lung Neoplasms | en_US |
dc.subject | Protein Kinase Inhibitors | en_US |
dc.subject | Retrospective Studies | en_US |
dc.subject | Cohort Studies | en_US |
dc.subject | Mutation | en_US |
dc.subject | Aged | en_US |
dc.subject | ErbB Receptors | en_US |
dc.title | Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG). | en |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-12-03 | |
rioxxterms.version | VoR | en |
rioxxterms.versionofrecord | 10.1093/oncolo/oyac022 | en |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | en |
dc.relation.isPartOf | The oncologist | en_US |
pubs.issue | 4 | en_US |
pubs.notes | Not known | en_US |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.publication-status | Published | en_US |
pubs.volume | 27 | en_US |
pubs.embargo.terms | Not known | en_US |
icr.researchteam | Thoracic Oncology | |
dc.contributor.icrauthor | Popat, Sanjay | |